Regulation and Mechanistic Investigation of CAR-T Cell Exhaustion by ADRB-Mediated β-Adrenergic Signaling

Jianming Xu(Chinese PLA General Hospital), Mingfeng Zhao(Nankai University), Cuicui Lv(Peking University), Xiaomei Zhang(Chinese PLA General Hospital), Bing Wang(Nankai University), Yu Zhang(Nankai University), Rui Zhang(Sun Yat-sen University), Shujing Guo(Tianjin Medical University), Mohan Zhao(Tianjin First Center Hospital), Xuwen Guan(Tianjin Medical University), Jile Liu(Tianjin Medical University)
SSRN Electronic Journal
January 1, 2025
10.2139/ssrn.5611225
Cited by 0

Related Papers

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687